Unicycive Therapeutics (UNCY) News Today → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free UNCY Stock Alerts $1.03 -0.05 (-4.63%) (As of 03:08 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 15 at 10:23 AM | finanznachrichten.deUnicycive Therapeutics, Inc.: Unicycive Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 15 at 7:03 AM | globenewswire.comUnicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical MeetingMay 15 at 5:54 AM | americanbankingnews.comUnicycive Therapeutics (NASDAQ:UNCY) Stock Rating Reaffirmed by HC WainwrightMay 14 at 12:08 AM | investorplace.comUNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q1 2024May 13 at 4:16 PM | globenewswire.comUnicycive Announces First Quarter 2024 Financial Results and Provides Business UpdateMay 9, 2024 | finance.yahoo.com3 Top Penny Stocks to Buy for Explosive Returns: April EditionApril 29, 2024 | finance.yahoo.comThese 2 ‘Strong Buy’ Penny Stocks Could Rally to $9, Says Piper SandlerApril 12, 2024 | markets.businessinsider.comBuy Rating Affirmed for Unicycive Therapeutics on Strong Trial Progress and Financial PositioningApril 10, 2024 | globenewswire.comUnicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity ConferenceApril 4, 2024 | markets.businessinsider.comUnicycive Therapeutics: A Strong Buy on OLC’s Potential to Revolutionize Hyperphosphatemia Treatment in CKDApril 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Unicycive Therapeutics Amidst Positive Milestones and Solid Financial FootingMarch 28, 2024 | investorplace.comUNCY Stock Earnings: Unicycive Therapeutics Misses EPS for Q4 2023March 28, 2024 | finance.yahoo.comUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateMarch 28, 2024 | globenewswire.comUnicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business UpdateMarch 25, 2024 | globenewswire.comUnicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association CongressMarch 16, 2024 | investing.comUnicycive reports progress in kidney injury treatment trialMarch 14, 2024 | markets.businessinsider.comBuy Rating on Unicycive Therapeutics Amidst Promising UNI-494 Drug Candidate ProspectsMarch 14, 2024 | globenewswire.comUnicycive Announces $50 Million Private PlacementMarch 13, 2024 | globenewswire.comUnicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT ConferenceMarch 12, 2024 | marketbeat.comUnicycive Therapeutics, Inc. (NASDAQ:UNCY) Short Interest Down 64.3% in FebruaryUnicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) was the recipient of a large drop in short interest in February. As of February 29th, there was short interest totalling 35,000 shares, a drop of 64.3% from the February 14th total of 98,000 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average trading volume of 311,300 shares, the days-to-cover ratio is presently 0.1 days.March 9, 2024 | finanznachrichten.deUnicycive Therapeutics, Inc.: Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)March 7, 2024 | globenewswire.comUnicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC)March 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Unicycive Therapeutics Amidst Promising UNI-494 Developments and FDA Orphan Drug DesignationMarch 5, 2024 | marketbeat.comUnicycive Therapeutics (NASDAQ:UNCY) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $4.50 price target on shares of Unicycive Therapeutics in a research report on Tuesday.March 4, 2024 | globenewswire.comUnicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant PatientsMarch 1, 2024 | marketbeat.comShort Interest in Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Grows By 46.7%Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Get Free Report) saw a significant growth in short interest in February. As of February 15th, there was short interest totalling 98,000 shares, a growth of 46.7% from the January 31st total of 66,800 shares. Currently, 0.4% of the shares of the stock are sold short. Based on an average daily volume of 272,800 shares, the days-to-cover ratio is currently 0.4 days.February 25, 2024 | benzinga.comUnicycive Therapeutics Stock (NASDAQ:UNCY), Short Interest ReportFebruary 25, 2024 | benzinga.comUnicycive Therapeutics Stock (NASDAQ:UNCY), Analyst Ratings, Price Targets, PredictionsFebruary 24, 2024 | msn.comUnicycive Therapeutics (UNCY) Price Target Increased by 14.13% to 4.46February 14, 2024 | finance.yahoo.comUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical MeetingFebruary 14, 2024 | globenewswire.comUnicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical MeetingFebruary 6, 2024 | finance.yahoo.comWe're Keeping An Eye On Unicycive Therapeutics' (NASDAQ:UNCY) Cash Burn RateJanuary 29, 2024 | finance.yahoo.comUnicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT ConferenceJanuary 24, 2024 | finance.yahoo.comUnicycive (UNCY) Up on Positive Hyperphosphatemia Study UpdateJanuary 23, 2024 | finanznachrichten.deUnicycive Therapeutics, Inc.: Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming MilestonesJanuary 23, 2024 | finance.yahoo.comUnicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming MilestonesDecember 21, 2023 | benzinga.comUnicycive Therapeutics Stock (NASDAQ:UNCY), Guidance and ForecastDecember 21, 2023 | benzinga.comUnicycive Therapeutics Stock (NASDAQ:UNCY) Dividends: History, Yield and DatesDecember 20, 2023 | markets.businessinsider.comBuy Rating for Unicycive Therapeutics Backed by Strategic Advancements and Market PotentialDecember 19, 2023 | markets.businessinsider.comStrong Buy Rating for Unicycive Therapeutics Amidst Clinical Advances and Positive Valuation OutlookDecember 18, 2023 | finance.yahoo.comUnicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on DialysisNovember 29, 2023 | finance.yahoo.comUnicycive Therapeutics to Participate in Two Investor Conferences in December 2023November 18, 2023 | finanznachrichten.deUnicycive Therapeutics, Inc.: Unicycive Announces Third Quarter 2023 Financial Results and Provides Business UpdateNovember 17, 2023 | finance.yahoo.comUnicycive Therapeutics Third Quarter 2023 Earnings: US$0.14 loss per share (vs US$0.37 loss in 3Q 2022)November 16, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Icecure Medical (ICCM) and Unicycive Therapeutics (UNCY)November 14, 2023 | finance.yahoo.comUnicycive Announces Third Quarter 2023 Financial Results and Provides Business UpdateOctober 23, 2023 | markets.businessinsider.comFDA, Unicycive Agree On Path To File NDA For Oxylanthanum CarbonateOctober 23, 2023 | finance.yahoo.comUnicycive Therapeutics Reaches Alignment with the FDA on Path to File New Drug Application for Oxylanthanum Carbonate (OLC)September 6, 2023 | finanznachrichten.deUnicycive Therapeutics, Inc.: Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhDSeptember 6, 2023 | finance.yahoo.comUnicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address The most important AI company you've never heard of (Ad)Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products. Get the full story on this secret AI company poised for massive growth UNCY Media Mentions By Week UNCY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. UNCY News Sentiment▼-0.170.55▲Average Medical News Sentiment UNCY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. UNCY Articles This Week▼91▲UNCY Articles Average Week Get Unicycive Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for UNCY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Cara Therapeutics News NextCure News Lexaria Bioscience News Sensei Biotherapeutics News Eyenovia News Bolt Biotherapeutics News Immuneering News VYNE Therapeutics News Xilio Therapeutics News Rockwell Medical News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:UNCY) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyElon’s New Device is About to Shock the WorldInvestorPlaceGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Unicycive Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
